78 research outputs found
CO2 storage risk minimization through systematic identification and assessment of faults: a Williston Basin case study
AbstractThe Williston Basin is considered a tectonically stable area with only a few major inactive faults. Over the last 50 years, extensive hydrocarbon exploration in the basin has demonstrated that smaller faults do exist and closer evaluation is necessary to determine the nature of this faulting. An area near the town of Dickinson, North Dakota, has been identified as a potential location for CO2 storage/enhanced oil recovery. A thorough geologic assessment of the area has identified structural anomalies that may indicate the presence of faulting, which, in turn, may affect precise CO2 storage site selection
Model development of the Aquistore CO2 storage project
AbstractThe Plains CO2 Reduction (PCOR) Partnership, through the Energy & Environmental Research Center, is collaborating with Petroleum Technology Research Centre in site characterization; risk assessment; public outreach; and monitoring, verification, and accounting activities at the Aquistore project. The PCOR Partnership constructed a static geological model to assess the potential volumetric storage capacity of the Aquistore site and provide the foundation for dynamic simulation for the dynamic CO2 storage capacity. Results of the predictive simulations will be used in the risk assessment process to define an overall monitoring plan and assure stakeholders that the injected CO2 will remain safely stored
Odin observations of H2O in the Galactic Centre
The Odin satellite has been used to detect emission and absorption in the
557-GHz H2O line in the Galactic Centre towards the Sgr A* Circumnuclear Disk
(CND), and the Sgr A +20 km/s and +50 km/s molecular clouds. Strong broad H2O
emission lines have been detected in all three objects. Narrow H2O absorption
lines are present at all three positions and originate along the lines of sight
in the 3-kpc Spiral Arm, the -30 km/s Spiral Arm and the Local Sgr Spiral Arm.
Broad H2O absorption lines near -130 km/s are also observed, originating in the
Expanding Molecular Ring. A new molecular feature (the ``High Positive Velocity
Gas'' - HPVG) has been identified in the positive velocity range of ~ +120 to
+220 km/s, seen definitely in absorption against the stronger dust continuum
emission from the +20 km/s and +50 km/s clouds and possibly in emission towards
the position of Sgr A* CND. The 548-GHz H2_18O isotope line towards the CND is
not detected at the 0.02 K (rms) level.Comment: 5 pages, 3 figures, accepted by A&A, special Odin Letters issu
Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach
We developed a series of interrelated locus-specific databases to store all published and unpublished genetic variation related to hemoglobinopathies and thalassemia and implemented microattribution to encourage submission of unpublished observations of genetic variation to these public repositories. A total of 1,941 unique genetic variants in 37 genes, encoding globins and other erythroid proteins, are currently documented in these databases, with reciprocal attribution of microcitations to data contributors. Our project provides the first example of implementing microattribution to incentivise submission of all known genetic variation in a defined system. It has demonstrably increased the reporting of human variants, leading to a comprehensive online resource for systematically describing human genetic variation in the globin genes and other genes contributing to hemoglobinopathies and thalassemias. The principles established here will serve as a model for other systems and for the analysis of other common and/or complex human genetic diseases
Bordetella pertussis Infection Exacerbates Influenza Virus Infection through Pertussis Toxin-Mediated Suppression of Innate Immunity
Pertussis (whooping cough) is frequently complicated by concomitant infections with respiratory viruses. Here we report the effect of Bordetella pertussis infection on subsequent influenza virus (PR8) infection in mouse models and the role of pertussis toxin (PT) in this effect. BALB/c mice infected with a wild-type strain of B. pertussis (WT) and subsequently (up to 14 days later) infected with PR8 had significantly increased pulmonary viral titers, lung pathology and mortality compared to mice similarly infected with a PT-deficient mutant strain (ΔPT) and PR8. Substitution of WT infection by intranasal treatment with purified active PT was sufficient to replicate the exacerbating effects on PR8 infection in BALB/c and C57/BL6 mice, but the effects of PT were lost when toxin was administered 24 h after virus inoculation. PT had no effect on virus titers in primary cultures of murine tracheal epithelial cells (mTECs) in vitro, suggesting the toxin targets an early immune response to increase viral titers in the mouse model. However, type I interferon responses were not affected by PT. Whole genome microarray analysis of gene expression in lung tissue from PT-treated and control PR8-infected mice at 12 and 36 h post-virus inoculation revealed that PT treatment suppressed numerous genes associated with communication between innate and adaptive immune responses. In mice depleted of alveolar macrophages, increase of pulmonary viral titers by PT treatment was lost. PT also suppressed levels of IL-1β, IL-12, IFN-γ, IL-6, KC, MCP-1 and TNF-α in the airways after PR8 infection. Furthermore PT treatment inhibited early recruitment of neutrophils and NK cells to the airways. Together these findings demonstrate that infection with B. pertussis through PT activity predisposes the host to exacerbated influenza infection by countering protective innate immune responses that control virus titers
Genetic copy number variants, cognition and psychosis: a meta-analysis and a family study
The burden of large and rare copy number genetic variants (CNVs) as well as certain specific CNVs increase the risk of developing schizophrenia. Several cognitive measures are purported schizophrenia endophenotypes and may represent an intermediate point between genetics and the illness. This paper investigates the influence of CNVs on cognition. We conducted a systematic review and meta-analysis of the literature exploring the effect of CNV burden on general intelligence. We included ten primary studies with a total of 18,847 participants and found no evidence of association. In a new psychosis family study, we investigated the effects of CNVs on specific cognitive abilities. We examined the burden of large and rare CNVs (>200 kb, <1% MAF) as well as known schizophrenia-associated CNVs in patients with psychotic disorders, their unaffected relatives and controls (N = 3428) from the Psychosis Endophenotypes International Consortium (PEIC). The carriers of specific schizophrenia-associated CNVs showed poorer performance than non-carriers in immediate (P = 0.0036) and delayed (P = 0.0115) verbal recall. We found suggestive evidence that carriers of schizophrenia-associated CNVs had poorer block design performance (P = 0.0307). We do not find any association between CNV burden and cognition. Our findings show that the known high-risk CNVs are not only associated with schizophrenia and other neurodevelopmental disorders, but are also a contributing factor to impairment in cognitive domains such as memory and perceptual reasoning, and act as intermediate biomarkers of disease risk.This work was supported by the Medical Research Council (G0901310) and the Wellcome Trust (grants 085475/B/08/Z, 085475/Z/08/Z). This study was
supported by the NIHR Biomedical Research Centre at University
College London Hospitals NHS Foundation Trust and University
College London and by the NIHR Biomedical Research Centre for
Mental Health at the South London and Maudsley NHS Foundation
Trust at King’s College London. Further support to EB: Mental Health
Research UK’s John Grace QC award, BMA Margaret Temple grants
2016 and 2006, MRC—Korean Health Industry Development Institute
Partnering Award (MC_PC_16014), MRC New Investigator Award
and a MRC Centenary Award (G0901310), National Institute of
Health Research UK post-doctoral fellowship, the Psychiatry Research
Trust, the Schizophrenia Research Fund, the Brain and Behaviour
Research foundation’s NARSAD Young Investigator Awards 2005,
2008, Wellcome Trust Research Training Fellowship, the NIHR
Biomedical Research Centre at UCLH, and the NIHR Biomedical
Research Centre for Mental Health at the South London and Maudsley
NHS Foundation Trust and Institute of Psychiatry King’s College
London. Further support to co-authors: The Brain and Behaviour
Research foundation’s (NARSAD’s) Young Investigator Award
(Grant 22604, awarded to CI). The BMA Margaret Temple grant 2016
to JT. A 2014 European Research Council Marie Curie award to A
Díez-Revuelta. HI has received funding from the European Union’s
Horizon 2020 research and innovation programme under the Marie
Sklodowska-Curie grant agreement No 747429. A Medical Research
Council doctoral studentship to JH-S, IA-Z and AB. A Mental Health
Research UK studentship to RM. VB is supported by a Wellcome
Trust Seed Award in Science (200589/Z/16/Z). FWO Senior Clinical
Fellowship to RvW. The infrastructure for the GROUP consortium is
funded through the Geestkracht programme of the Dutch Health
Research Council (ZON-MW, grant number 10-000-1001), and
matching funds from participating pharmaceutical companies (Lundbeck, AstraZeneca, Eli Lilly, Janssen Cilag) and universities and
mental health care organisations (Amsterdam: Academic Psychiatric
Centre of the Academic Medical Centre and the mental health institutions: GGZ Ingeest, Arkin, Dijk en Duin, GGZ Rivierduinen,
Erasmus Medical Centre, GGZ Noord Holland Noord. Groningen:
University Medical Centre Groningen and the mental health institutions: Lentis, GGZ Friesland, GGZ Drenthe, Dimence, Mediant,
GGNet Warnsveld, Yulius Dordrecht and Parnassia psycho-medical
centre The Hague. Maastricht: Maastricht University Medical Centre
and the mental health institutions: GGZ Eindhoven en De Kempen,
GGZ Breburg, GGZ Oost-Brabant, Vincent van Gogh voor Geestelijke
Gezondheid, Mondriaan, Virenze riagg, Zuyderland GGZ, MET ggz,
Universitair Centrum Sint-Jozef Kortenberg, CAPRI University of
Antwerp, PC Ziekeren Sint-Truiden, PZ Sancta Maria Sint-Truiden,
GGZ Overpelt, OPZ Rekem. Utrecht: University Medical Centre Utrecht and the mental health institutions Altrecht, GGZ Centraal and
Delta). The Santander cohort was supported by Instituto de Salud
Carlos III (PI020499, PI050427, PI060507), SENY Fundació (CI
2005-0308007), Fundacion Ramón Areces and Fundacion Marqués de
Valdecilla (API07/011, API10/13). We thank Valdecilla Biobank for
providing the biological PAFIP samples and associated data included
in this study and for its help in the technical execution of this work; we
also thank IDIVAL Neuroimaging Unit for its help in the acquisition
and processing of imaging PAFIP data
Novel Common Genetic Susceptibility Loci for Colorectal Cancer
BACKGROUND: Previous genome-wide association studies (GWAS) have identified 42 loci (P < 5 × 10-8) associated with risk of colorectal cancer (CRC). Expanded consortium efforts facilitating the discovery of additional susceptibility loci may capture unexplained familial risk. METHODS: We conducted a GWAS in European descent CRC cases and control subjects using a discovery-replication design, followed by examination of novel findings in a multiethnic sample (cumulative n = 163 315). In the discovery stage (36 948 case subjects/30 864 control subjects), we identified genetic variants with a minor allele frequency of 1% or greater associated with risk of CRC using logistic regression followed by a fixed-effects inverse variance weighted meta-analysis. All novel independent variants reaching genome-wide statistical significance (two-sided P < 5 × 10-8) were tested for replication in separate European ancestry samples (12 952 case subjects/48 383 control subjects). Next, we examined the generalizability of discovered variants in East Asians, African Americans, and Hispanics (12 085 case subjects/22 083 control subjects). Finally, we examined the contributions of novel risk variants to familial relative risk and examined the prediction capabilities of a polygenic risk score. All statistical tests were two-sided. RESULTS: The discovery GWAS identified 11 variants associated with CRC at P < 5 × 10-8, of which nine (at 4q22.2/5p15.33/5p13.1/6p21.31/6p12.1/10q11.23/12q24.21/16q24.1/20q13.13) independently replicated at a P value of less than .05. Multiethnic follow-up supported the generalizability of discovery findings. These results demonstrated a 14.7% increase in familial relative risk explained by common risk alleles from 10.3% (95% confidence interval [CI] = 7.9% to 13.7%; known variants) to 11.9% (95% CI = 9.2% to 15.5%; known and novel variants). A polygenic risk score identified 4.3% of the population at an odds ratio for developing CRC of at least 2.0. CONCLUSIONS: This study provides insight into the architecture of common genetic variation contributing to CRC etiology and improves risk prediction for individualized screenin
New insights into the genetic etiology of Alzheimer's disease and related dementias
Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/'proxy' AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele
Peri-operative red blood cell transfusion in neonates and infants: NEonate and Children audiT of Anaesthesia pRactice IN Europe: A prospective European multicentre observational study
BACKGROUND: Little is known about current clinical practice concerning peri-operative red blood cell transfusion in neonates and small infants. Guidelines suggest transfusions based on haemoglobin thresholds ranging from 8.5 to 12 g dl-1, distinguishing between children from birth to day 7 (week 1), from day 8 to day 14 (week 2) or from day 15 (≥week 3) onwards. OBJECTIVE: To observe peri-operative red blood cell transfusion practice according to guidelines in relation to patient outcome. DESIGN: A multicentre observational study. SETTING: The NEonate-Children sTudy of Anaesthesia pRactice IN Europe (NECTARINE) trial recruited patients up to 60 weeks' postmenstrual age undergoing anaesthesia for surgical or diagnostic procedures from 165 centres in 31 European countries between March 2016 and January 2017. PATIENTS: The data included 5609 patients undergoing 6542 procedures. Inclusion criteria was a peri-operative red blood cell transfusion. MAIN OUTCOME MEASURES: The primary endpoint was the haemoglobin level triggering a transfusion for neonates in week 1, week 2 and week 3. Secondary endpoints were transfusion volumes, 'delta haemoglobin' (preprocedure - transfusion-triggering) and 30-day and 90-day morbidity and mortality. RESULTS: Peri-operative red blood cell transfusions were recorded during 447 procedures (6.9%). The median haemoglobin levels triggering a transfusion were 9.6 [IQR 8.7 to 10.9] g dl-1 for neonates in week 1, 9.6 [7.7 to 10.4] g dl-1 in week 2 and 8.0 [7.3 to 9.0] g dl-1 in week 3. The median transfusion volume was 17.1 [11.1 to 26.4] ml kg-1 with a median delta haemoglobin of 1.8 [0.0 to 3.6] g dl-1. Thirty-day morbidity was 47.8% with an overall mortality of 11.3%. CONCLUSIONS: Results indicate lower transfusion-triggering haemoglobin thresholds in clinical practice than suggested by current guidelines. The high morbidity and mortality of this NECTARINE sub-cohort calls for investigative action and evidence-based guidelines addressing peri-operative red blood cell transfusions strategies. TRIAL REGISTRATION: ClinicalTrials.gov, identifier: NCT02350348
- …